why choose us

First received: June 01, 2023

Clinical Trial: LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

Study Status: Completed

Recruit Status: RECRUITING

Condition: Bronchiolitis Obliterans Syndrome

Study Type: INTERVENTIONAL


Official Title: A Randomized, Placebo-controlled Phase 2 Study to Demonstrate the Safety and Efficacy of the Addition of LAM-001 to Standard Immunosuppression Therapy for Chronic Lung Allograft Dysfunction (BOS).

Brief Summary: The goal of this clinical trial is to learn about the safety and effectiveness of LAM-001 in patients who have developed bronchiolitis obliterans syndrome (BOS), a form of chronic rejection, after lung transplantation.The main questions it aims to answer are:Is LAM-001 safe in these patients?Is LAM-001 effective in slowing BOS progression?Participants will:Be randomly assigned to inhale either LAM-001 or placebo (a look-alike substance that contains no active drug) daily for 48 weeksAttend 10 study visits (mixture…

Read more